Literature DB >> 2804380

Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation.

H C Schouten1, P J Bierman, W P Vaughan, A Kessinger, J M Vose, D D Weisenburger, J O Armitage.   

Abstract

Patients with disseminated follicular non-Hodgkin's lymphoma (NHL) are only occasionally cured with standard chemotherapy regimens. Although most of these tumors are initially responsive to chemotherapy, in 40% to 70% of patients the lymphoma will eventually transform to an NHL of higher grade malignancy and a poorer prognosis. We treated 18 patients having an original diagnosis of follicular NHL with high-dose therapy and autologous bone marrow transplantation. The lymphomas of 10 of the patients had already undergone histologic transformation and eight still had a follicular histologic pattern. The former group had been followed for a longer time from the diagnosis of NHL and had been more extensively treated with conventional chemotherapy regimens. All eight patients with follicular NHL at the time of transplantation are alive for 246+ to 1,804+ days and seven of the patients are in complete remission. In contrast, of the 10 patients in histologic transformation only 1 is alive and in CR. This reflects the inability of these patients to tolerate the high-dose chemotherapy and myelosuppression as well as resistance of their lymphoma to this therapy. This difference in survival between the two groups was highly significant (P = .002). We conclude that the outcome of patients with follicular NHL transplanted early before histologic transformation is better than for those who are transplanted later in the course of their illness. Because of the relapsing behavior of follicular NHL, a longer follow-up is necessary to prove any impact on the natural history of the disease.

Entities:  

Mesh:

Year:  1989        PMID: 2804380

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Role of hematopoietic stem cell transplant in the management of follicular lymphoma.

Authors:  Matthew Foster; Don A Gabriel; Thomas Shea
Journal:  Oncologist       Date:  2009-06-26

Review 2.  Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Authors:  Nishitha Reddy; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

Review 3.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

4.  Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.

Authors:  S Yano; T Mori; Y Kanda; J Kato; C Nakaseko; S Fujisawa; N Tomita; R Sakai; K Shono; T Saitoh; N Aotsuka; N Kobayashi; T Saito; S Takahashi; H Kanamori; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

Review 5.  The role of autografting in lymphoma.

Authors:  D W Milligan; S G Long
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

Review 6.  [Transplantation of hematopoietic stem cells. II: Indications for transplantation of hematopoietic stem cells after myeloablative therapy].

Authors:  H Link; H J Kolb; W Ebell; D K Hossfeld; A Zander; D Niethammer; H Wandt; H Grosse-Wilde; U W Schaefer
Journal:  Med Klin (Munich)       Date:  1997-09-15

7.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Authors:  Brian K Link; Matthew J Maurer; Grzegorz S Nowakowski; Stephen M Ansell; William R Macon; Sergei I Syrbu; Susan L Slager; Carrie A Thompson; David J Inwards; Patrick B Johnston; Joseph P Colgan; Thomas E Witzig; Thomas M Habermann; James R Cerhan
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

8.  Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.

Authors:  Mehdi Hamadani; Don M Benson; Craig C Hofmeister; Patrick Elder; William Blum; Pierluigi Porcu; Ramiro Garzon; Kristie A Blum; Thomas S Lin; Guido Marcucci; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2009-03-09       Impact factor: 5.742

9.  Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

Authors:  Baldeep Wirk; Timothy S Fenske; Mehdi Hamadani; Mei-Jie Zhang; Zhen-Huan Hu; Görgün Akpek; Mahmoud D Aljurf; Philippe Armand; Ernesto Ayala; Veronika Bachanova; Brian Bolwell; Mitchell S Cairo; Amanda Cashen; Yi-Bin Chen; Luciano J Costa; Shatha Farhan; César O Freytes; James L Gajewski; John Gibson; Gregory A Hale; Leona A Holmberg; Jack W Hsu; David J Inwards; Rummurti T Kamble; Dipnarine Maharaj; Richard T Maziarz; Reinhold Munker; Rajneesh Nath; Nishitha M Reddy; Craig B Reeder; David A Rizzieri; Craig S Sauter; Bipin N Savani; Harry C Schouten; Anna Sureda; Julie M Vose; Edmund K Waller; Peter H Wiernik; Robert Peter Gale; Linda J Burns; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-15       Impact factor: 5.742

Review 10.  The management of follicular lymphoma.

Authors:  A Z Rohatiner; T A Lister
Journal:  Drugs       Date:  1994       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.